News
While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...
We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on NVO.
People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...
For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
The best metric is not weight, but a particularly toxic kind of fat.
For the first time, scientists have pitted the two most popular weight loss drugs against each other in a direct competition ...
The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...
Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...
As a Biden administration ban on so-called “junk fees” took effect Monday, Ticketmaster said it would start displaying the ...
Weight loss drugs and jabs have become more popular and a recent study looked at the effectiveness of two drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results